Addex Therapeutics emerges from under the radar

Having had to retrench four years ago, Swiss biotech Addex Therapeutics has been focusing on its in-house platform around allosteric modulation. Speaking at the Biotech Showcase 2018, CEO Tim Dyer explains to Scrip how the company now has the resources to advance dipraglurant, its lead asset, into registration studies for PD-LID, while continuing to develop its other programs.